Figure 4

Drugs with differential activity by mutational status. (A) PI3K inhibitor AZD6482 demonstrates increased activity in PIK3CA mutant versus wild-type cell lines. (B) When analysis was restricted to HNSCC cell lines, AZD6482 and FAK inhibitor PF-562271 demonstrated increased activity in PIK3CA mutant lines. (C) AZD6482 and JNK Inhibitor VIII had increased activity in EGFR amplified cell lines relative to wild-type lines. Points represent individual observations, while boxes show estimates of the respective median, interquartile range, and extrema.